KAS
LXRX icon

Kestra Advisory Services’s Lexicon Pharmaceuticals LXRX Stock Holding History

Kestra Advisory Services’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,500
Closed -$23.3K – 2842
2024
Q4 		$23.3K Buy
31,500
+16,000
+103% +$19.3K ﹤0.01% 2635
2024
Q3 		$24.3K Hold
15,500
– – ﹤0.01% 2524
2024
Q2 		$26K Buy
15,500
+1,000
+7% +$1.79K ﹤0.01% 2581
2024
Q1 		$34.8K Buy
+14,500
New +$31.1K ﹤0.01% 2415
2023
Q3 		– Sell
-14,257
Closed -$32.6K – 2181
2023
Q2 		$32.6K Buy
+14,257
New +$37.8K ﹤0.01% 2063

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kestra Advisory Services's LXRX Position: Q1 2025 in Review

Kestra Advisory Services sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2025, closing a stake of 31,500 shares — an estimated $23.3K sold.

Kestra Advisory Services first reported a position in LXRX in Q2 2023 and held it in 5 quarters. The position peaked at $34.8K in Q1 2024. 127 funds tracked by Wall St. Rank hold LXRX as of Q1 2025.

  • Kestra Advisory Services reported no remaining Lexicon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Kestra Advisory Services sold 31,500 Lexicon Pharmaceuticals shares in Q1 2025, an estimated $23.3K.
  • Kestra Advisory Services first reported a position in Lexicon Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Kestra Advisory Services's Lexicon Pharmaceuticals position peaked at $34.8K in Q1 2024.
  • 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2025.

Based on Kestra Advisory Services's 13F filing for Q1 2025, filed 14 May 2025.